Valeant selling 4 assets for $2.1B in cash grab: 4 takeaways

To combat its $30 billion debt, Lovell, Canada-based Valeant Pharmaceuticals is selling its Dendreon cancer business and three of its skincare brands for $2.12 billion.

Advertisement

Here’s what you should know.

1. Valeant is selling its Dendreon immunotherapy prostate cancer business to China-based Sanpower Group for $819.9 million.

2. Additionally, Valeant is selling its CeraVe, AMBI Skincare and AcneFree skincare brands to Île-de-France-based L’Oreal for $1.3 billion.

The three product lines yielded an annual revenue of $168 million for Valeant.

3. Valeant expects to close on both transactions in early 2017.

4. The sales’ proceeds will pay back some of Valeant’s term loan debt.

More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Bitman Stewart of Digestive Care
Integrated Endoscopy seeks $4.4M for executive compensation: 3 key notes
Hallmark Health Medical Associates names gastroenterologist Dr. Michael Newman president: 3 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.